Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
Go back to Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension| INSMED (NASDAQ: INSM) | Delayed: 106.73 +0.09 (0.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $106.64 | 52 Week High | $19.30 | |||
| Open | $105.80 | 52 Week Low | $9.02 | |||
| Day High | $107.88 | P/E | N/A | |||
| Day Low | $105.09 | EPS | $-1.69 | |||
| Volume | 1,084,956 | |||||
